Free tool
Expedited programs
Last checked: Nov 18, 2026Source: FDA CDER lists and Drugs@FDAMethods & limitations
Approvals by program and year
An approval can count under several programs. Since 2012, when breakthrough therapy designation began.
- Breakthrough therapy
- Accelerated approval
- Priority review
- Orphan
View as table
| Year | Breakthrough therapy | Accelerated approval | Priority review | Orphan |
|---|---|---|---|---|
| 2012 | 0 | 8 | 48 | 29 |
| 2013 | 3 | 4 | 47 | 30 |
| 2014 | 14 | 9 | 71 | 52 |
| 2015 | 20 | 9 | 76 | 58 |
| 2016 | 21 | 7 | 75 | 59 |
| 2017 | 30 | 10 | 119 | 100 |
| 2018 | 38 | 9 | 147 | 130 |
| 2019 | 25 | 10 | 132 | 100 |
| 2020 | 31 | 20 | 139 | 126 |
| 2021 | 30 | 17 | 139 | 97 |
| 2022 | 26 | 9 | 117 | 94 |
| 2023 | 17 | 12 | 111 | 118 |
| 2024 | 30 | 11 | 114 | 136 |
| 2025 | 35 | 13 | 119 | 164 |
| 2026 | 15 | 5 | 106 | 104 |
Breakthrough therapy
On CDER's list of approvals for drugs with Breakthrough Therapy designation. Source: CDER Breakthrough Therapy Designation Approvals list.
Most approvals since 2012
Accelerated approval
On CDER's list of accelerated approvals based on a surrogate endpoint. Source: CDER accelerated approvals based on a surrogate endpoint.
Most approvals since 2012
- Novartis12
Priority review
FDA gave the original application priority review: a 6-month goal instead of 10. Source: Drugs@FDA review priority.
Most approvals since 2012
- Merck & Co.112
- Novartis90
- AbbVie83
- GSK52
Orphan
Drugs@FDA marks at least one approval of this application as for an orphan-designated use (a rare disease). Source: Drugs@FDA orphan marking.
Most approvals since 2012
Looking ahead? The PDUFA calendar lists announced FDA action dates.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.